BR112012024585A2 - inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas - Google Patents
inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicasInfo
- Publication number
- BR112012024585A2 BR112012024585A2 BR112012024585A BR112012024585A BR112012024585A2 BR 112012024585 A2 BR112012024585 A2 BR 112012024585A2 BR 112012024585 A BR112012024585 A BR 112012024585A BR 112012024585 A BR112012024585 A BR 112012024585A BR 112012024585 A2 BR112012024585 A2 BR 112012024585A2
- Authority
- BR
- Brazil
- Prior art keywords
- chronic active
- cell
- signaling
- receptor signaling
- cell receptor
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title abstract 8
- 230000001684 chronic effect Effects 0.000 title abstract 7
- 108091008875 B cell receptors Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000003950 B-cell lymphoma Diseases 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003990 molecular pathway Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901310P | 2010-03-30 | 2010-03-30 | |
| US201061425525P | 2010-12-21 | 2010-12-21 | |
| PCT/EP2011/054709 WO2011120911A1 (en) | 2010-03-30 | 2011-03-28 | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012024585A2 true BR112012024585A2 (pt) | 2016-05-31 |
Family
ID=44710357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012024585A BR112012024585A2 (pt) | 2010-03-30 | 2011-03-28 | inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8748428B2 (https=) |
| EP (1) | EP2552428A1 (https=) |
| JP (1) | JP2013523678A (https=) |
| KR (2) | KR101461767B1 (https=) |
| CN (1) | CN102821759A (https=) |
| AR (1) | AR080737A1 (https=) |
| AU (1) | AU2011234644B2 (https=) |
| BR (1) | BR112012024585A2 (https=) |
| CA (1) | CA2795456A1 (https=) |
| MX (1) | MX2012011341A (https=) |
| RU (1) | RU2012146083A (https=) |
| WO (1) | WO2011120911A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4556010A3 (en) | 2011-11-30 | 2025-07-23 | Emory University | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| KR101723786B1 (ko) | 2014-03-28 | 2017-04-06 | 가톨릭대학교 산학협력단 | Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물 |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| JP2019524700A (ja) * | 2016-07-14 | 2019-09-05 | ミングサイト ファーマシューティカルズ，インク． | 癌の処置 |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| WO2020092924A1 (en) * | 2018-11-02 | 2020-05-07 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489608A (en) | 1989-12-21 | 1996-02-06 | Goedecke Aktiengesellschaft | Indolocarbazole derivatives and the use thereof |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| NO308798B1 (no) | 1993-12-07 | 2000-10-30 | Lilly Co Eli | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| YU49315B (sh) | 1995-11-20 | 2005-06-10 | Elli Lilly And Company | Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje |
| US6645970B2 (en) | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| AU2002221810B2 (en) | 2000-11-07 | 2005-06-23 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| AU2004230952A1 (en) | 2003-04-09 | 2004-10-28 | Millenium Pharmaceuticals, Inc. | Beta-carbolines useful for treating inflammatory disease |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| DE602004014965D1 (de) | 2003-10-24 | 2008-08-21 | Lilly Co Eli | Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen |
| PE20060608A1 (es) | 2004-10-13 | 2006-08-22 | Wyeth Corp | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k |
| AU2006217744A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors |
| AU2006217742A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006268908A1 (en) * | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| PL1954699T3 (pl) | 2005-11-22 | 2013-01-31 | Kudos Pharm Ltd | Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
| KR101438245B1 (ko) | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
-
2011
- 2011-03-28 CN CN2011800155365A patent/CN102821759A/zh active Pending
- 2011-03-28 RU RU2012146083/15A patent/RU2012146083A/ru not_active Application Discontinuation
- 2011-03-28 MX MX2012011341A patent/MX2012011341A/es not_active Application Discontinuation
- 2011-03-28 WO PCT/EP2011/054709 patent/WO2011120911A1/en not_active Ceased
- 2011-03-28 KR KR1020127025582A patent/KR101461767B1/ko not_active Expired - Fee Related
- 2011-03-28 CA CA2795456A patent/CA2795456A1/en not_active Abandoned
- 2011-03-28 EP EP11713996A patent/EP2552428A1/en not_active Withdrawn
- 2011-03-28 US US13/073,652 patent/US8748428B2/en not_active Expired - Fee Related
- 2011-03-28 BR BR112012024585A patent/BR112012024585A2/pt not_active IP Right Cessation
- 2011-03-28 KR KR1020147022716A patent/KR20140107685A/ko not_active Withdrawn
- 2011-03-28 JP JP2013501783A patent/JP2013523678A/ja active Pending
- 2011-03-28 AU AU2011234644A patent/AU2011234644B2/en not_active Ceased
- 2011-03-30 AR ARP110101038A patent/AR080737A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011234644A1 (en) | 2012-10-11 |
| KR101461767B1 (ko) | 2014-11-13 |
| EP2552428A1 (en) | 2013-02-06 |
| US20110245256A1 (en) | 2011-10-06 |
| KR20140107685A (ko) | 2014-09-04 |
| AR080737A1 (es) | 2012-05-02 |
| MX2012011341A (es) | 2012-11-12 |
| US8748428B2 (en) | 2014-06-10 |
| JP2013523678A (ja) | 2013-06-17 |
| AU2011234644B2 (en) | 2014-07-17 |
| KR20120133389A (ko) | 2012-12-10 |
| CA2795456A1 (en) | 2011-10-06 |
| WO2011120911A1 (en) | 2011-10-06 |
| RU2012146083A (ru) | 2014-05-10 |
| CN102821759A (zh) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024585A2 (pt) | inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas | |
| SV2009003283A (es) | Inhibidores de la actividad de la akt | |
| DOP2009000159A (es) | Inhibidores de la poli(adp-ribosa) polimerasa | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| ECSP099724A (es) | Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| MY182650A (en) | Treatment of cancer with tor kinase inhibitors | |
| MX373925B (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
| WO2010124283A3 (en) | Methods and compositions relating to hematologic malignancies | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112012021334A2 (pt) | material biodegradável, contendo silício, para terapia anti-inflamatória. | |
| UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| BR112018010012A2 (pt) | regimes de dosagem de melflufen para câncer | |
| MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| CL2009000660A1 (es) | Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor. | |
| PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |